Plain-English translation of NCT05728658 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study testing a new medication called for patients with mature B-cell cancers (certain types of leukemia and lymphoma) that have returned or stopped responding to prior treatment. Researchers are finding the right dose and checking whether the medication is safe and effective, both when given alone and when combined with another existing drug called Orelabrutinib.
Current treatments don't work for everyone with these blood cancers, especially when the disease comes back or resists previous therapy. This study explores whether this new treatment option could help patients who have limited choices.
You likely qualify if…
You likely don't qualify if…
You will take the medication by mouth daily, starting with a gradual ramp-up schedule during the first cycle. Depending on which group you're assigned to, you may take this medication alone or combined with another drug. You'll visit the clinic regularly for blood tests, physical exams, and imaging scans to check how well the medication is working and watch for any side effects. The study continues until the cancer progresses, you experience unacceptable side effects, or you choose to stop.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
China